BridgeBio Oncology Therapeutics News and Activities

BridgeBio Oncology Therapeutics is owned by BridgeBio.

BridgeBio is one of the...

• Russell 3000;
• TOB Iconic 10,000.

BridgeBio is a company listed under the stock ticker BBIO (US).

View the org chart displaying its 24 main executives

Most searched biographies at BridgeBio Oncology Therapeutics

• Pedro Beltran, Chief Executive Officer
• Peter Lebowitz, Director
• Jake Bauer, Non-Executive Director

Popular executive movements at BridgeBio Oncology Therapeutics

• Eli Wallace, Chief Executive Officer, has left the company  (posted on April 23 2026).
• Neil Kumar, who was Director, is promoted to Executive Chairman of the Board  (posted on April 23 2026).
• Idan Elmelech, who was Senior Vice President, Strategy and Business Development, is promoted to Chief Operating Officer  (posted on April 23 2026).

Click here to view some more movements at BridgeBio Oncology Therapeutics

Popular executive movements at BridgeBio

• Maggie Sweeney has joined the company as Senior Director, Clinical Quality and Compliance  (posted on May 6 2026).
• Julie Miller Everett, who was Chief Business Officer, is promoted to Chief Operating Officer, Skeletal Dysplasias  (posted on April 23 2026).
• Josh Loehrer who was Chief People Officer, becomes Chief Operating Officer, Cardiovascular  (posted on April 23 2026).

Click here to view some more movements at BridgeBio

Create your alert
to follow the executive moves at BridgeBio Oncology Therapeutics.

BridgeBio has 2,405 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ona Therapeutics has just announced a $87 Million fundraising (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by BridgeBio Oncology Therapeutics

Social media about BridgeBio Oncology Therapeutics

• BridgeBio Oncology Therapeutics on Wikipedia, Google News & Yahoo Finance
• BridgeBio Oncology Therapeutics on LinkedIn, X (Twitter) & YouTube